Vertex faces regulatory delays for Journavx and reports VX-993 Phase 2 trial failure

Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint

Revvity launches reagent technology for targeted therapeutics

Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research

Eli Lilly inaugurates global capability centre in hyderabad to advance AI initiatives

The expansion will bring together talent in AI, data science, and engineering to build the digital foundation needed to accelerate drug discovery and delivery

NIH develops AI agent to improve accuracy of gene set analysis

The system, called GeneAgent, cross-checks its own initial predictions for accuracy against information from established, expert-curated databases

Illumina launches new assay for tumor profiling

he new version features a streamlined sample-to-analysis workflow, built-in HRD detection, faster turnaround, and lower tissue requirements

JB Pharma Q1 FY26 PAT up at 14% to Rs. 202 Cr

Lilly's Mounjaro shows heart health benefits in head-to-head trial with Trulicity

The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity

Agilent and TIFR Hyderabad join hands to boost metabolism and health research

Roche presents new Alzheimer’s research at AAIC 2025

Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease

Roche updates on Elevidys gene therapy for Duchenne muscular dystrophy in EU

Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne